Global Blood Therapeutics Reports Recent Business Progress and Third Quarter 2015 Financial Results

Foundation Medicine to Present at the Goldman Sachs SMID Cap Growth Conference

Afferent Pharmaceuticals Announces Phase 2 Clinical Trial with AF-219 in Cough in Idiopathic Pulmonary Fibrosis (IPF) Patients

Global Blood Therapeutics Announces Multiple Data Presentations Supporting GBT440 Program for Hypoxemic Pulmonary Disorders, Including Idiopathic Pulmonary Fibrosis

Voyager Therapeutics Announces Pricing of Initial Public Offering

Zafgen Announces Third Quarter 2015 Financial Results

Blueprint Medicines Reports Third Quarter 2015 Financial Results

Blueprint Medicines Highlights Advances in Preclinical Discovery Efforts

Foundation Medicine and Collaborators to Present New Clinical Data Supporting Comprehensive Genomic Profiling in Advanced Sarcomas and Hematologic Malignancies with FoundationOne® Heme

Warp Drive Bio Announces Breakthrough in the Ability to Target the Previously Undruggable Oncogene RAS

Warp Drive Bio Announces Formation of Board of World-Leading Oncology Experts to Focus on Company’s RAS Program

Agios Announces Data from Dose-Escalation Phase 1 Study of AG-120 in Patients with IDH1 Mutant Positive Advanced Solid Tumors

CytomX Highlights Data from Multiple Probody Pipeline Programs at Investor Event During AACR-NCI-EORTC Conference

Rhythm Presents Cardiovascular Safety Data from Phase 1b/2a Clinical Trials of Setmelanotide in Obesity

Rhythm Presents Positive Data from Phase 1b Study of Setmelanotide for the Treatment of Genetic Obesity

Agios Reports Third Quarter 2015 Financial Results

Agios to Present New Data From Lead Programs at the 2015 ASH Annual Meeting

bluebird bio to present LentiGlobin® BB305 Clinical Data and bb2121 Preclinical Data at Annual Meeting of the American Society of Hematology

CytomX and MD Anderson Cancer Center Enter Into Strategic Collaboration for Probody-Enabled CAR-NK Cell Therapies

Global Blood Therapeutics Announces New GBT440 Data in Sickle Cell Disease to be Presented at the American Society of Hematology (ASH) Annual Meeting

SAGE Announces Third Quarter 2015 Financial Results and Recent Pipeline Progress

MyoKardia Announces Presentations at American Heart Association Scientific Sessions 2015

Eleven Biotherapeutics Reports Third Quarter 2015 Financial Results

bluebird bio Announces Participation in 24th Annual Credit Suisse Healthcare Conference

Allena Pharmaceuticals To Present Phase 2 Data on ALLN-177 Program at ASN Kidney Week 2015

bluebird bio Reports Third Quarter 2015 Financial Results and Recent Operational Progress

Agios to Present at Credit Suisse 24th Annual Healthcare Conference on Tuesday, November 10

CytomX Appoints Matthew Young to Board of Directors

Foundation Medicine Announces 2015 Third Quarter Results and Recent Highlights

Jounce Therapeutics Appoints Elizabeth Trehu, M.D., to Chief Medical Officer

MyoKardia Announces Closing of Initial Public Offering

SAGE Announces Presentations at Upcoming November Investor Conferences

Zafgen to Host Conference Call to Discuss Third Quarter 2015 Financial Results

Foundation Medicine Announces Roche Pharmaceuticals (Israel) Ltd. to Commence Commercial Activities in Support of its Molecular Information Products in Oncology

Warp Drive Bio to Present First Program Using Small Molecule Assisted Receptor Targeting (SMART) Platform Against the RAS Oncogene at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

SAGE to Report Third Quarter 2015 Financial Results on Thursday, November 5, 2015

Agios to Webcast Conference Call of Third Quarter 2015 Financial Results on November 5, 2015

MyoKardia Announces Pricing of Initial Public Offering

Eleven Biotherapeutics to Report Third Quarter 2015 Financial Results on November 4, 2015

TARIS Biomedical® Raises $32 Million and Expands Leadership Team and Board of Directors

Agios to Present Clinical Data from Ongoing AG-120 Phase 1 Trial in Advanced Solid Tumors at AACR-NCI-EORTC

Data from CytomX\'s Probodyâ„¢ Pipeline to be Presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Zafgen Announces Beloranib Program Update

bluebird bio Announces Presentation at Cooley’s Anemia Foundation Symposium

Agios Outlines Key Clinical Development & Research Strategies

Zafgen Announces Partial Clinical Hold Affecting Beloranib Trials

Eleven Biotherapeutics Completes Enrollment in Pivotal Phase 3 Study of Isunakinra (EBI-005) in Patients with Allergic Conjunctivitis

Third Rock Ventures Launches Decibel Therapeutics with $52 Million Series A Financing to Discover New Medicines to Protect, Repair and Restore Hearing

CytomX Announces Closing of Initial Public Offering and Full Exercise of Underwriters\' Option to Purchase Additional Shares

Global Blood Therapeutics to Present at BIO Investor Forum